A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), led by Assistant Professor Anand Jeyasekharan, has discovered a unique combination of oncogenes ...
Jul 19, 2023
0
0
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...
Jun 4, 2023
0
54
Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%. Receiving a ...
Jun 1, 2023
0
17
In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for ...
Feb 1, 2023
0
2
A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma ...
May 12, 2022
0
18
Japanese collaborative research teams have discovered new mechanisms of action by extracellular vesicles (EV) for the development and malignant progression of lymphomas.
Mar 28, 2022
0
54
Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...
Dec 10, 2021
0
1
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, ...
Apr 8, 2021
0
11
Among patients with lymphoma admitted to the hospital for severe COVID-19, those treated with B-cell-depleting therapies within the previous 12 months had an increased risk of prolonged hospital stay and death, according ...
Feb 4, 2021
0
3
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
